Home › Research › Biomarkers
Blood-based biomarkers for Alzheimer's disease and cognitive function from mid- to late life
Wang X, Bakulski KM, Karvonen-Gutierrez CA, Park SK, Morgan D, Albin RL, Paulson HL.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023-12-21
Topic: Amyloid, tau and blood-test diagnosis
Introduction We investigated associations of Alzheimer's disease (AD) serum biomarkers with longitudinal changes in cognitive function from mid- to late life among women. Methods The study population included 192 women with the median age of 53.3 years at baseline, from the Study of Women's Health Across the Nation Michigan Cohort, followed up over 14 years. Associations between baseline serum amyloid β (Aβ)42, the Aβ42/40 ratio, phosphorylated tau181 (p-tau181), and total tau with longitudinal changes in cognition were evaluated using linear mixed effects models. Results After adjusting for confounders, lower Aβ42/40 ratios were associated with faster declines in the Digit Span Backward Test. Higher p-tau181 also showed a borderline statistically significant association with more rapid decline in the Symbol Digit Modalities Test. Discussion Our findings suggest that mid-life serum AD biomarkers could be associated with accelerated cognitive decline from mid- to late life in women. Future studies with larger samples are needed to validate and extend our findings. Highlights This study investigates midlife serum AD biomarkers on longitudinal cognitive function changes in women. Mid-life serum AD biomarkers are associated with accelerated cognitive decline. A decrease in the Aβ42/40 ratio was associated with a faster decline in the DSB score. A higher p-tau181 concentration was associated with a faster decline in the SDMT score.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wang, X., Bakulski, K. M., Karvonen-Gutierrez, C. A., Park, S. K., Morgan, D., Albin, R. L., et al. (2024). Blood-based biomarkers for Alzheimer's disease and cognitive function from mid- to late life. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.13583
Vancouver
Wang X, Bakulski KM, Karvonen-Gutierrez CA, Park SK, Morgan D, Albin RL, et al. Blood-based biomarkers for Alzheimer's disease and cognitive function from mid- to late life. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. doi:10.1002/alz.13583. PMID: 38126555.
BibTeX
@article{wang2024-38126555,
author = {Wang, X. and Bakulski, K. M. and Karvonen-Gutierrez, C. A. and Park, S. K. and Morgan, D. and Albin, R. L. and Paulson, H. L.},
title = {{Blood-based biomarkers for Alzheimer's disease and cognitive function from mid- to late life}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2024},
doi = {10.1002/alz.13583},
pmid = {38126555},
url = {https://doi.org/10.1002/alz.13583}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results After adjusting for confounders, lower Aβ42/40 ratios were associated with faster declines in the Digit Span Backward Test.
- Higher p-tau181 also showed a borderline statistically significant association with more rapid decline in the Symbol Digit Modalities Test.
- Discussion Our findings suggest that mid-life serum AD biomarkers could be associated with accelerated cognitive decline from mid- to late life in women.
- Future studies with larger samples are needed to validate and extend our findings.
- Mid-life serum AD biomarkers are associated with accelerated cognitive decline.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Participants192
- Evidence strengthModerate
How this study scored 72/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 42 of the 58 points we could judge it on, which is 72 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 192 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38126555) |
| Free to read | 2 / 2 | Free to read |
| Points | 42 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 42 of the 58 points we could judge it on is 72 out of 100. |
| Total | 72 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Biomarkers
Also in Biomarkers
204 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.